I’m really not sure why management issued this news release today. Have they really just been sitting around on this file since December waiting for the phone to ring?  

Perhaps sitting around waiting for the phone to ring is why management has yet to get a licensing deal with upfront money, has yet to partner on any other indications, has yet to get additional top tier analyst coverage and has yet to leverage that extremely valuable BET bromodomain blood bank?  Perhaps it’s time for a new business development strategy that involves proactively picking up the phone?  

We all know the human and financial cost of HIV/AIDS is enormous.  IMO an opportunity worth actively persuing.

From today’s NR, “....interested HIV/AIDS stakeholders such as patient advocacy groups, government health bodies, major phamaceutical companies, and/or non-government research organization (NRO’s) are encouraged to contact Resverlogix to further the research and development of apabetalone as a therapeutic for HIV-1 eradication,” stated Donald McCaffrey, President”

From Dec 12/17 NR “....we would like to extend an open invitation to any interested parties, that have the resources, to expedite a new program utilizing either apabetalone or one of our other follow-on BET inhibitors to test this hypothesis and provide a novel therapeutic for this terrible disease.”

Would seem from these news releases that management is exectly where it was six months ago on this file...... square one.  Disappointing.